PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells
暂无分享,去创建一个
D. Brenner | M. Erion | Brian Rady | A. Pocai | D. Dhar | T. Kisseleva | T. Nishio | Xiao Liu
[1] D. Brenner,et al. Molecular and cellular mechanisms of liver fibrosis and its regression , 2020, Nature Reviews Gastroenterology & Hepatology.
[2] A. Sigova,et al. Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings , 2020, Cells.
[3] Juanjuan Wu,et al. Mechanistic insights into the effects of SREBP1c on hepatic stellate cell and liver fibrosis , 2020, Journal of cellular and molecular medicine.
[4] R. Martinez,et al. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems , 2020, Cellular and molecular gastroenterology and hepatology.
[5] M. Trauner,et al. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[6] R. Loomba,et al. PNPLA3 Genotype and Risk of Liver and All‐Cause Mortality , 2020, Hepatology.
[7] M. Trauner,et al. PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells , 2019, Hepatology communications.
[8] M. Herman,et al. Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity , 2019, JHEP reports.
[9] S. Romeo,et al. The role of PNPLA3 in health and disease. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[10] Richard G. Lee,et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice , 2019, Molecular metabolism.
[11] S. Milstein,et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. , 2017, Cell metabolism.
[12] M. Trauner,et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells , 2017, Hepatology.
[13] V. Wong,et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.
[14] B. Motta,et al. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis , 2016, Human molecular genetics.
[15] A. Singal,et al. PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum , 2016, Journal of clinical and translational hepatology.
[16] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[17] Shasha Zhang,et al. Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis , 2015, Scientific Reports.
[18] Jonathan C. Cohen,et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis , 2014, Hepatology.
[19] R. Siebert,et al. Genetic Characteristics of the Human Hepatic Stellate Cell Line LX-2 , 2013, PloS one.
[20] M. Pollheimer,et al. Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice , 2012, Hepatology.
[21] V. Olkkonen,et al. PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. , 2012, American journal of physiology. Endocrinology and metabolism.
[22] Hongyu Zhao,et al. A common variant in the patatin‐like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents , 2010, Hepatology.
[23] T. Liang,et al. The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease , 2010, Hepatology.
[24] E. Bugianesi,et al. Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.
[25] Alexander Pertsemlidis,et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.
[26] Yosuke Osawa,et al. TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.
[27] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[28] D. Brenner,et al. Human hepatic stellate cell isolation and characterization , 2017, Journal of Gastroenterology.